Effect of Infusion of Recipient Spleen Cells at Different Time after Murine Haploidentical Hematopoietic Stem Cell Transplantation on Graft Versus Host Disease.
- Author:
Jun-Hui WANG
1
;
Lei DENG
1
;
Lu WANG
1
;
Chen LIANG
1
;
Yi WANG
1
;
Tie-Qiang LIU
1
;
Shan HUANG
1
;
Ya-Jing HUANG
1
;
Bo CAI
1
;
Zheng DONG
1
;
Hong-Li ZUO
1
;
Qi-Yun SUN
1
;
Jian-Hui QIAO
1
;
Chang-Lin YU
1
;
Kai-Xun HU
1
;
Hui-Sheng AI
1
;
Mei GUO
2
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(3):866-872
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of infusing G-CSF mobilized recipient spleen cells at different time after haploidentical stem cell transplantation(HSCT) on graft-versus-host disease (GVHD) in mice and its possible mechanism.
METHODSForty mice after HSCT were randomly divided into 4 groups (n=10): GVHD positive control group (control group), 1st d recipient cell infusion group after transplantation (+1 d group), 4th d recipient cell infusion group after transplantation(+4 d group), 7th d recipient cell infusion group after transplantation(+7 d group). The mice in control group were injected the normal saline of same equivalent with experimental group which were given the same amount of G-CSF-mobilized recipient spleen cells. The general manifestation and pathological change of GVHD were observed. The expression changes of CD3CD4, CD3CD8cell subsets and FasL in peripheral blood were detected by flow cytometry.
RESULTSThe incidence of GVHD was significantly decreased in +4 d group and the median survival time was longer than 60 days, which was significantly higher than that of control group (24 d), +1 d group (21 d), +7 d group (28 d). (P<0.01, P<0.01, P<0.01). The Fasl expression of peripheral blood T lymphocytes in +4 d group were significantly lower than that in the other 3 groups(P<0.05).
CONCLUSIONThe +4 d infusion of G-CSF mobilized recipient spleen cells on 4th day after haploidentical HSC transplantation can inhibit the expression of FasL in donor T lymphocytes, and significantly reduce the incidence of GVHD.